#Sweden #Orexo #AmorphOX #Uppsala #intranasal vaccine

Orexo's Groundbreaking Advances in Intranasal Vaccine Development

In a significant advancement for vaccine technology, Orexo AB, a Swedish pharmaceutical company, has unveiled positive in-vivo proof-of-concept data for its innovative powder-based intranasal vaccine, formulated using its proprietary AmorphOX technology. This announcement, made on April 10, 2025, is a major milestone in their collaboration with Abera Bioscience, a developer known for its robust research credentials in vaccines and molecular biology.

The collaboration, initiated in December 2024, aims to enhance mucosal vaccine development by integrating Orexo's advanced powder drug delivery system with Abera's innovative BERA™ vaccine platform. The initial study, which was conducted on rats, tested both liquid and powder formulations of Abera's influenza vaccine. Remarkably, both forms triggered a strong systemic antibody response within the serum (IgG), as well as localized responses in the nose and lungs (IgA), indicating that the AmorphOX technology effectively preserves the vaccine's efficacy.

This development is particularly noteworthy as an intranasal vaccine could significantly improve disease prevention strategies, especially in scenarios of potential future pandemics. The advantage of powder formulations is clear: they not only offer cost-effectiveness but also eliminate the need for cold chain logistics typically required for liquid vaccines. As Robert Rönn, SVP and Head of Research and Development at Orexo, remarked, the results provide critical insight into how vaccines can reach broader populations, underscoring their commitment to innovative drug delivery solutions.

Additionally, Mats Lundgren, CSO of Abera Bioscience, pointed out the logistical advantages inherent in using powder formulations during mass vaccination campaigns. Simplified distribution, combined with thermal stability and self-administration potential, positions the AmorphOX technology as a game-changer in pandemic preparedness efforts.

The global health landscape has shifted dramatically in recent years, underscoring the urgency for adaptable and resilient vaccination strategies. As countries grapple with the ongoing impacts of infectious diseases, the need for technologies that can flexibly adapt to varying distribution capabilities has never been greater. The collaboration between Orexo and Abera aims to meet this need, pursuing research that optimally positions vaccine formulations for against a broad range of pathogens.

In its 30 years of operation, Orexo has built a reputable portfolio of pharmacologic innovations by focusing on tailoring drug delivery technologies to meet critical healthcare needs. The firm is presently recognized primarily for treatments targeting opioid use disorder, while also developing a variety of therapies for other therapeutic areas in collaboration with key industry partners. With the recent good fortune in securing positive vaccine data, the company's reach in the public health domain seems set for expansion, as they continually seek solutions that address pressing global health concerns.

The next steps for Orexo include further studies to explore the benefits of powder formulations in human clinical trials as they seek to bring this promising intranasal vaccine candidate to market. As the world prepares for potential future health crises, innovations like Orexo's AmorphOX technology stand at the forefront of reshaping how vaccines can be developed, distributed, and administrated effectively, aiding in the broad fight against infectious diseases worldwide.

To find out more about Orexo and their pioneering approaches to pharmaceutical innovations, visit their official website or follow them on their social media platforms.

About Orexo

Orexo AB is a Swedish company known for developing groundbreaking pharmaceuticals that cater to significant medical needs, evidenced by its strong focus on opioid use disorder treatments and a commitment to innovation in drug delivery systems.

About AmorphOX®

AmorphOX is Orexo's proprietary drug delivery platform, characterized by its unique powder formulations that demonstrate excellent stability and dissolution properties, providing a promising foundation for future vaccine developments.